Table 2.
Comparison of the negative and positive PANSS scores between the medicine and placebo groups
| Groups | P value | Effect size | ||
|---|---|---|---|---|
| Mean±SD (95%CI) | ||||
| Placebo | Medicine | |||
| Negative PANSS1 | ||||
| NP12 | 30.2±3.07 (28.8-31.5) | 28±4.11 (26.1-30.0) | 0.068 | 1.79 |
| NP23 | 30.2±3.38 (28.3-31.7) | 23.33±3.77 (21.6-25.1) | 0.001 | |
| DNP4 | 0±0.85 (-0.37-0.37) | 4.66±1.32 (4.04-5.27) | 0.001 | |
| Positive PANSS5 | ||||
| PP16 | 18.15±1.92 (17.30-18.99) | 19.22±2.26 (18.1-80.26) | 0.239 | 0.7 |
| PP27 | 18.45±2.32 (17.43-19.46) | 18.11±2.9 (16.77-9.45) | 0.124 | |
| dPP8 | -0.3±1.08 (-0.77-0.17) | 1.11±2.16 (0.11-2.11) | 0.25 | |
1: Positive and negative syndrome scale for schizophrenia; 2: Negative PANSS1- baseline; 3: Negative PANSS2- week 12; 4: Difference negative PANSS=NP1-NP2; 5: Positive and negative syndrome scale for schizophrenia; 6: Positive PANSS1; 7: Positive PANSS2; 8:Difference positive PANSS=PP1-PP2